Title:Expanding Arsenal against Neurodegenerative Diseases Using Quercetin
Based Nanoformulations: Breakthroughs and Bottlenecks
Volume: 21
Issue: 7
Author(s): Sukriti Vishwas, Rajesh Kumar, Rubiya Khursheed, Arya Kadukkattil Ramanunny, Rajan Kumar, Ankit Awasthi, Leander Corrie, Omji Porwal, Mohammed F. Arshad, Mohammed Kanan Alshammari, Abdulrahman A. Alghitran, Ashwaq N. Qumayri, Saif M. Alkhaldi, Abdulaziz Khalaf Alshammari, Dinesh Kumar Chellappan*, Gaurav Gupta, Trudi Collet, Jon Adams, Kamal Dua, Monica Gulati and Sachin Kumar Singh*
Affiliation:
- Department of Life Sciences, School of Pharmacy,
International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
- School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411
Punjab, India
- Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia
Keywords:
Quercetin, antioxidant, neuroinflammation, neurodegenerative disease, novel drug delivery systems, Alzheimer’s disease.
Abstract: Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such as
coriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrus
fruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects against
various diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less explored
in clinical research as a nutraceutical. The present review covers various neuroprotective actions of
Qu against various neurodegenerative diseases (NDs) such as Alzheimer’s, Parkinson’s, Huntington’s,
and Amyotrophic lateral sclerosis. A literature search was conducted to systematically review
the various mechanistic pathways through which Qu elicits its neuroprotective actions and the challenges
associated with raw Qu that compromise therapeutic efficacy. The nanoformulations developed
to enhance Qu’s therapeutic efficacy are also covered. Various ongoing/completed clinical trials
related to Qu in treating various diseases, including NDs, are also tabulated. Despite these many
successes, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinical
studies, probably due to poor drug loading and stability of the formulation, time-consuming
steps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are required
in this area to reach Qu nanoformulations to the clinical level.
